Podocyte Effacement Closely Links to suPAR Levels at Time of Posttransplantation Focal Segmental Glomerulosclerosis Occurrence and Improves With Therapy
Serum soluble urokinase-type plasminogen activator receptor (suPAR) has been put forth as the a candidate for the elusive “FSGS” factor that may lead to aggressive and early recurrence post-transplant. This study of patients with recurrent FSGS post-transplant found higher suPAR levels in patients with more extensive podocyte damage on renal biopsy. However, this study is limited to patients with recurrent disease, and cannot answer the question of whether suPAR levels can predict recurrence. Given that another study (http://journals.lww.com/transplantjournal/Abstract/2013/08270/Urine_But_Not_Serum_Soluble_Urokinase_Receptor.10.aspx) has shown high suPAR levels in patients with advanced chronic kidney disease of different causes, the relationship between suPAR and disease recurrence remains unclear.